Based on the Caredx Inc stock forecast from 4 analysts, the average analyst target price for Caredx Inc is USD 28.40 over the next 12 months. Caredx Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Caredx Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Caredx Inc’s stock price was USD 21.09. Caredx Inc’s stock price has changed by +2.33% over the past week, -15.34% over the past month and +66.06% over the last year.
No recent analyst target price found for Caredx Inc
No recent average analyst rating found for Caredx Inc
Company Overview Caredx Inc
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California. Read Less
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transp...Read More
Frequently Asked Questions About Caredx Inc (CDNA) Stock
Based on ratings from 4 analysts Caredx Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, 1 sell and hold ratings.
Unfortunately we do not have enough data on CDNA's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for CDNA is USD 28.40 over the next 12 months. The maximum analyst target price is USD 40 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on CDNA's stock to indicate if its overvalued.
The last closing price of CDNA's stock was USD 21.09.
The most recent market capitalization for CDNA is USD 1.34B.
Based on targets from 4 analysts, the average taret price for CDNA is projected at USD 28.40 over the next 12 months.
This means that CDNA's stock price may go up by +34.66% over the next 12 months.
We can't find any ETFs which contains Caredx Inc's stock.
As per our most recent records Caredx Inc has 635 Employees.
Caredx Inc's registered address is 8000 Marina Boulevard, South San Francisco, CA, United States, 94005.
You can get more information about it from Caredx Inc's website at https://caredx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Caredx Inc (CDNA) Stock
Based on ratings from 4 analysts Caredx Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, 1 sell and hold ratings.
Unfortunately we do not have enough data on CDNA's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for CDNA is USD 28.40 over the next 12 months. The maximum analyst target price is USD 40 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on CDNA's stock to indicate if its overvalued.
The last closing price of CDNA's stock was USD 21.09.
The most recent market capitalization for CDNA is USD 1.34B.
Based on targets from 4 analysts, the average taret price for CDNA is projected at USD 28.40 over the next 12 months.
This means that CDNA's stock price may go up by +34.66% over the next 12 months.
We can't find any ETFs which contains Caredx Inc's stock.
As per our most recent records Caredx Inc has 635 Employees.
Caredx Inc's registered address is 8000 Marina Boulevard, South San Francisco, CA, United States, 94005.
You can get more information about it from Caredx Inc's website at https://caredx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CDNA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
